A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II multicenter randomized open-label clinical study that will determine
whether treatment with Lactofiltrum (orally administered tablets) in combination with
antibiotic therapy (metronidazole) is effective in women with bacterial vaginosis.
Lactofiltrum is a composite drug that includes enterosorbent lignin and prebiotic Lactulose.
It's supposed that supplement of Lactofiltrum to a standard therapy of bacterial vaginosis
(metronidazole administered orally) improves women's general state, leads to better recovery
of clinical, microbiological, biochemical and histological features of the disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Avva Rus, JSC
Collaborators:
Kirov Regional clinical Center of Perinatology Kirov State Medical Academy